Patents by Inventor Steven Brian Gendreau

Steven Brian Gendreau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of treating PR-positive, luminal A breast cancer with PI3K inhibitor, pictilisib
    Patent number: 10004748
    Abstract: Methods and compositions are provided for treating breast cancer in patients with a PI3K inhibitor, GDC-0941 in combination with an endocrine therapy agent.
    Type: Grant
    Filed: May 20, 2015
    Date of Patent: June 26, 2018
    Assignee: Genentech, Inc.
    Inventors: Mika K. Derynck, Lori Friedman, Steven Brian Gendreau, Sandra Milan
  • METHODS OF TREATING PR-POSITIVE, LUMINAL A BREAST CANCER WITH PI3K INHIBITOR, PICTILISIB
    Publication number: 20150335650
    Abstract: Methods and compositions are provided for treating breast cancer in patients with a PI3K inhibitor, GDC-0941 in combination with an endocrine therapy agent.
    Type: Application
    Filed: May 20, 2015
    Publication date: November 26, 2015
    Applicant: Genentech, Inc.
    Inventors: Mika K. Derynck, Lori Friedman, Steven Brian Gendreau, Sandra Milan
  • MAPKs as modifiers of the rac, axin, and beta-catenin pathways and methods of use
    Patent number: 8067180
    Abstract: Human MAPK genes are identified as modulators of the Rac, axin, and beta-catenin pathways, and thus are therapeutic targets for disorders associated with defective Rac, axin, and beta-catenin function. Methods for identifying modulators of Rac, axin, and beta-catenin, comprising screening for agents that modulate the activity of MAPK are provided.
    Type: Grant
    Filed: November 24, 2003
    Date of Patent: November 29, 2011
    Assignee: Exelixis, Inc.
    Inventors: Lisa C. Kadyk, George Ross Francis, Steven Brian Gendreau, Emery G. Dora, III, Michael R. Costa, Kim Lickteig
  • TAOJIKs as modifiers of the beta-catenin pathway and methods of use
    Patent number: 8003315
    Abstract: Human TAOJIK genes are identified as modulators of the beta-catenin pathway, and thus are therapeutic targets for disorders associated with defective beta-catenin function. Methods for identifying modulators of beta-catenin, comprising screening for agents that modulate the activity of TAOJIK are provided.
    Type: Grant
    Filed: December 12, 2002
    Date of Patent: August 23, 2011
    Assignee: Exelixis, Inc.
    Inventors: Michael A. Costa, Steven Brian Gendreau, Emery G. Dora, III, Monique Nicoll, Lenore Urbani, Jeffrey S. Larson
  • GFATS As Modifiers of the AXIN Pathway and Methods of Use
    Publication number: 20110167505
    Abstract: Human GFAT genes are identified as modulators of the Axin pathway, and thus are therapeutic targets for disorders associated with defective Axin function. Methods for identifying modulators of Axin, comprising screening for agents that modulate the activity of GFAT are provided.
    Type: Application
    Filed: June 20, 2006
    Publication date: July 7, 2011
    Applicant: EXELIXIS, INC.
    Inventors: Steven Brian Gendreau, Emery G. Dora, III, Kim Lickteig
  • Mapks as Modifiers of the Rac, Axin, and Beta-Catenin Pathways and Methods of Use
    Publication number: 20080229435
    Abstract: Human MAPK genes are identified as modulators of the Rac, axin, and beta-catenin pathways, and thus are therapeutic targets for disorders associated with defective Rac, axin, and beta-catenin function. Methods for identifying modulators of Rac, axin, and beta-catenin, comprising screening for agents that modulate the activity of MAPK are provided.
    Type: Application
    Filed: November 24, 2003
    Publication date: September 18, 2008
    Applicant: EX-ELIXIS, INC
    Inventors: Lisa C. Kadyk, George Ross Francis, Steven Brian Gendreau, Emery G. Dora, Michael R. Costa, Kim Lickteig
  • MBCATs as modifiers of the beta-catenin pathway and methods of use
    Publication number: 20030224406
    Abstract: Human MBCAT genes are identified as modulators of the beta-catenin pathway, and thus are therapeutic targets for disorders associated with defective beta-catenin function. Methods for identifying modulators of beta-catenin, comprising screening for agents that modulate the activity of MBCAT are provided.
    Type: Application
    Filed: February 28, 2003
    Publication date: December 4, 2003
    Inventors: Michael A. Costa, Steven Brian Gendreau, Emery G. Dora, Monique Nicoll, Timothy S. Heuer
  • TAOJIKs as modifiers of the beta-catenin pathway and methods of use
    Publication number: 20030157531
    Abstract: Human TAOJIK genes are identified as modulators of the beta-catenin pathway, and thus are therapeutic targets for disorders associated with defective beta-catenin function. Methods for identifying modulators of beta-catenin, comprising screening for agents that modulate the activity of TAOJIK are provided.
    Type: Application
    Filed: December 12, 2002
    Publication date: August 21, 2003
    Inventors: Michael A. Costa, Steven Brian Gendreau, Emery G. Dora, Monique Nicoll, Lenore Urbani, Jeffrey S. Larson